

TRANSGENOMIC INC
Form 8-K
November 30, 2010

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
November 29, 2010

TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)

| | | |
|---------------------------------------------------------------------------------|------------------------------------------------------------------------|---------------------------------------------------|
| Delaware (State of Incorporation) | 000-30975 (Commission File Number) | 911789357 (IRS Employer Identification Number) |
| 12325 Emmet Street, Omaha, Nebraska (Address of principal executive offices) | (402) 452-5400 (Registrant's telephone number, including area code) | 68164 (Zip Code) |

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 1.01 Entry into a Material Definitive Agreement

On November 29, 2010, Transgenomic, Inc. issued a press release announcing the signing of a definitive agreement for Transgenomic to acquire the diagnostic business of Clinical Data, Inc. (Nasdaq GM:CLDA).

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

(99) Press release dated November 29, 2010, announcing Transgenomic, Inc.'s signing of a definitive agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 29, 2010

TRANSGENOMIC, INC.

By: /s/ Brett L. Frevert
Brett L. Frevert
Interim Chief Financial Officer